Skip to main content
Top
Published in: Child's Nervous System 12/2021

01-12-2021 | Tuberous Sclerosis | Case Report

Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report

Authors: Sergio Cavalheiro, Marcos Devanir Silva da Costa, Rosana Richtmann

Published in: Child's Nervous System | Issue 12/2021

Login to get access

Abstract

Introduction

The association between cardiac rhabdomyoma and intraventricular tumors and/or subcortical nodules is characteristic of tuberous sclerosis complex (TSC). Patients with TSC may have refractory seizures, autistic behavior, and cognitive decline.

Case report

The patient received the fetal diagnosis of TSC at the age of 19 weeks of gestations, where presented at prenatal ultrasound cardiac and brain tumors. Fetal MRI showed a lesion in the right and left lateral ventricles near the foramen of Monro associated with subependymal lesions along the entire ependyma of the lateral ventricles and several subcortical tubercles, and the fetal Doppler echocardiogram revealed three cardiac lesions. The fetus underwent intrauterine treatment with everolimus and presented regression and subsequent stabilization of the cardiac and brain lesions; additionally, the patient did not develop seizures or autism and presented good neuropsychomotor development.

Conclusion

It is the first evidence that mTOR inhibitors may help to prevent neurological complications associated with TSC.
Literature
1.
go back to reference H IJ (2002) I. Perinatal brain tumors: a review of 250 cases. Pediatr Neurol 27:333–342CrossRef H IJ (2002) I. Perinatal brain tumors: a review of 250 cases. Pediatr Neurol 27:333–342CrossRef
8.
go back to reference Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, Jansen A, Jóźwiak S, Kingswood JC, Kotulska K, Macaya A, Moavero R, Nabbout R, Zonnenberg BA (2016) The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. Drugs 76:551–565. https://doi.org/10.1007/s40265-016-0552-9CrossRefPubMed Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, Jansen A, Jóźwiak S, Kingswood JC, Kotulska K, Macaya A, Moavero R, Nabbout R, Zonnenberg BA (2016) The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. Drugs 76:551–565. https://​doi.​org/​10.​1007/​s40265-016-0552-9CrossRefPubMed
9.
go back to reference Velíšek L, Moshé SL (2008) Pathophysiology of seizures and epilepsy in the immature brain: cells, synapses, and circuits. In: Pellock J M, Bourgeois B F D, Dodson E W NDRJ, R S (eds) Pediatric epilepsy: diagnosis and therapy, 3rd Editio. Demos Medical Publishing, New York Velíšek L, Moshé SL (2008) Pathophysiology of seizures and epilepsy in the immature brain: cells, synapses, and circuits. In: Pellock J M, Bourgeois B F D, Dodson E W NDRJ, R S (eds) Pediatric epilepsy: diagnosis and therapy, 3rd Editio. Demos Medical Publishing, New York
10.
go back to reference Jóźwiak S, Kotulska K, Domańska-Pakieła D, Łojszczyk B, Syczewska M, Chmielewski D, Dunin-Wąsowicz D, Kmieć T, Szymkiewicz-Dangel J, Kornacka M, Kawalec W, Kuczyński D, Borkowska J, Tomaszek K, Jurkiewicz E, Respondek-Liberska M (2011) Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 15:424–431. https://doi.org/10.1016/j.ejpn.2011.03.010CrossRefPubMed Jóźwiak S, Kotulska K, Domańska-Pakieła D, Łojszczyk B, Syczewska M, Chmielewski D, Dunin-Wąsowicz D, Kmieć T, Szymkiewicz-Dangel J, Kornacka M, Kawalec W, Kuczyński D, Borkowska J, Tomaszek K, Jurkiewicz E, Respondek-Liberska M (2011) Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 15:424–431. https://​doi.​org/​10.​1016/​j.​ejpn.​2011.​03.​010CrossRefPubMed
11.
go back to reference French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388:2153–2163. https://doi.org/10.1016/S0140-6736(16)31419-2CrossRefPubMed French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388:2153–2163. https://​doi.​org/​10.​1016/​S0140-6736(16)31419-2CrossRefPubMed
Metadata
Title
Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report
Authors
Sergio Cavalheiro
Marcos Devanir Silva da Costa
Rosana Richtmann
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 12/2021
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-021-05218-4

Other articles of this Issue 12/2021

Child's Nervous System 12/2021 Go to the issue